ERRATA

Errata for “Genetic Testing for Psychopharmacology: Is It Ready for Prime Time?”

The article “Genetic Testing for Psychopharmacology: Is It Ready for Prime Time?” by Laura G. Leahy, DrNP, APRN, PMH-CNS/FNP, BC, which was published in the March 2017 issue of the Journal of Psychosocial Nursing and Mental Health Services (volume 55, number 3, pp. 19-23), has been amended to include factual corrections. Errors were identified subsequent to its original publication. Several acronyms were incorrect: GRIK3 should have been GRIK1 and ORM1 should have been OPRM1. In the Table, for COMT, Met/Met should have been Val/Val; for CYP450, UM 2B6 should have been EM 2B6 and PM 2C9 should have been IM 2C9. The Table footnote has been changed to include: Potential treatment options and interpretations of the implications are based on evidence in the literature and the author’s clinical experience. On page 22, the following statement has been changed: In addition, Jane’s genetic profile reveals ultrarapid metabolism of drugs metabolized by CYP450 2C19. On page 22, the following statement has been changed: Jane’s profile also reveals the val/val variant on the COMT gene. On page 22, the following statement has been changed: As buproprion XL is metabolized by CYP2B6 and Jane is an extensive metabolizer for that enzyme, she may require doses at the higher end of the dosing range to experience the full benefits of the medication. On page 23, the following statement has been changed: As Jane is an intermediate metabolizer for CYP2C9, lower doses or less frequent dosing of naproxen would be indicated. The online article and its erratum are considered the version of record.

doi:10.3928/02793695-20170517-01